What is Recipharm?
Recipharm operates as a critical partner to the global pharmaceutical industry, providing comprehensive services that span the entire product lifecycle. From early-stage development and clinical trial support to large-scale commercial manufacturing, the company acts as a vital intermediary for drug developers. Its market position is defined by its ability to navigate complex regulatory environments while maintaining high-quality production standards across its international facilities. As a CDMO, Recipharm is essential for companies looking to outsource technical manufacturing processes, thereby optimizing their own operational efficiency and time-to-market for new therapeutic agents.
How much funding has Recipharm raised?
Recipharm has raised a total of $612.4M across 8 funding rounds:
Share Placement
$20M
Debt
$101.3M
Stock Offering
$87M
Debt
$160.2M
Stock Offering
$29.5M
Debt
$106.8M
Stock Offering
$54.2M
Stock Offering
$53.4M
Share Placement (2011): $20M with participation from Nordea Funds
Debt (2012): $101.3M led by Swedbank AB
Stock Issuance/Offering (2014): $87M supported by Undisclosed
Debt (2014): $160.2M featuring DNB, Handelsbanken, and Swedbank
Stock Issuance/Offering (2016): $29.5M backed by Undisclosed
Debt (2016): $106.8M with participation from Undisclosed
Stock Issuance/Offering (2018): $54.2M led by Undisclosed
Stock Issuance/Offering (2020): $53.4M supported by Lansforsakringar, Polar Capital, and Gladiator
Key Investors in Recipharm
Lansforsakringar
A major Swedish banking and insurance group that provides comprehensive financial services and investment management to both individual and corporate clients.
Polar Capital
A specialized investment management firm focused on active, high-conviction strategies across global equity markets and thematic sectors.
Swedbank
A leading Nordic-Baltic banking group that offers a wide range of financial products and corporate lending services to support industrial growth.
What's next for Recipharm?
Looking ahead, the strategic deployment of the $53.4M is expected to accelerate Recipharm's operational expansion and technological integration. Given the current enterprise-level funding context, the firm is well-positioned to pursue inorganic growth opportunities or invest in advanced manufacturing infrastructure to meet the rising demand for specialized pharmaceutical products. By focusing on high-growth therapeutic areas and enhancing its service portfolio, Recipharm aims to reinforce its status as a preferred partner for global pharmaceutical enterprises. The company's ability to secure consistent backing from major financial institutions suggests a stable outlook for future innovation and market consolidation.
See full Recipharm company page
